Kondoh M, Ueda M, Ichihashi M, Mishima Y
Department of Dermatology, Kobe University School of Medicine, Japan.
Melanoma Res. 1993 Aug;3(4):241-5.
ME491 expression was examined by immunohistochemistry in the different stages of various types of human malignant melanomas. In addition, the primary and metastatic lesions in five patients were studied to compare the ME491 antigen expression between these lesions in a single patient. A large proportion of cells from melanoma pre-canceroses showed strong ME491 expression, whereas the proportion of negatively stained tumour cells increased in the melanomas invading the dermis and in metastatic melanomas. In addition, a comparison of five sets of primary tumour and its metastatic lesion revealed decreased expression of this antigen in metastases. These results show that the reduction or loss of ME491 antigen expression is associated with increased invasiveness and metastatic ability of human malignant melanoma, suggesting that ME491 may act as an anti-metastatic gene.
通过免疫组织化学方法检测了ME491在各种类型人类恶性黑色素瘤不同阶段的表达情况。此外,对5例患者的原发性和转移性病变进行了研究,以比较同一患者这些病变之间ME491抗原的表达。来自黑色素瘤癌前病变的大部分细胞显示出ME491的强表达,而在侵入真皮的黑色素瘤和转移性黑色素瘤中,阴性染色肿瘤细胞的比例增加。此外,对5组原发性肿瘤及其转移病变的比较显示,该抗原在转移灶中的表达降低。这些结果表明,ME491抗原表达的减少或丧失与人类恶性黑色素瘤侵袭性和转移能力的增加有关,提示ME491可能作为一种抗转移基因发挥作用。